28 April 2022 | News
Anteris Technologies has entered a research partnership with Yale University and the Yale Cardiovascular Research Group (YCRG) in regard to its aortic valve science technology
Image credit: shutterstock
Australia's Anteris Technologies has announced its research partnership with Yale University and the Yale Cardiovascular Research Group (YCRG) led by Dr. Alexandra Lansky, MD, Director of the YCRG, Professor of Medicine at Yale University of Medicine. The aim of this partnership is to further study the various ways and mechanisms hemodynamic function after transcatheter aortic valve replacement in patients with severe aortic stenosis can be impacted by product design.
Yale University and Yale Cardiovascular Research Group have decades of experience in pre- clinical and clinical cardiovascular research and have been at the forefront of many therapies and health advances over the years.
“This partnership is a testament of Anteris’ commitment to continue to advance valve science through rigorous, scientific research with best-in-class academic centers.” Anteris CEO, Wayne Paterson, said.
Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.
Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.
Anteris’ DurAVRTM 3D single-piece aortic heart valve replacement addresses the needs of tomorrow’s younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.